Showing 5541-5550 of 5909 results for "".
- Ivantis Announces Publication of Comparative MIGS Clinical Trial Resultshttps://modernod.com/news/ivantis-announces-publication-of-comparative-migs-clinical-trial-results/2476486/Ivantis, developer of the Hydrus Microstent, announced that the 12-month results of the COMPARE study for minimally invasive glaucoma surgery (MIGS) were accepted into the journal Ophthalmology, according to a company news release. COMPARE is the first prospective, multicenter, ra
- GenSight Biologics Reports Positive Follow-Up Results of Phase 3 Trial in LHONhttps://modernod.com/news/gensight-biologics-reports-positive-follow-up-results-of-phase-3-trial-in-lhon/2476475/GenSight Biologics announced results from the second scheduled readout, at week 72, of the RESCUE phase 3 clinical trial evaluating the safety and efficacy of a single intravitreal injection of GS010 (rAAV2/2-ND4) in 39 subjects whose visual loss due to 11778-ND4 Leber Hereditar
- Ophthotech Changes Name to Iveric bio as it Transitions to Gene Therapy Companyhttps://modernod.com/news/ophthotech-changes-name-to-iveric-bio-as-it-transitions-to-gene-therapy-company/2476473/Ophthotech announced that as part of its transition strategy to focus on discovering and developing novel gene therapy solutions to treat orphan inherited retinal diseases (IRDs) with unmet medical needs, the company
- Visioneering Technologies Creates Educational Series for Eye Care Practitionershttps://modernod.com/news/visioneering-technologies-creates-educational-series-for-eye-care-practitioners/2476471/Visioneering Technologies, maker of the NaturalVue Multifocal 1 Day contact lenses, announced the creation of a new educational series for eye care practitioners featuring some of the world’s leading researchers and clinicians, according to a company news release. The first installment of
- Proxy Advisory Firms Back Allergan in Battle with Dissident Shareholder Appaloosahttps://modernod.com/news/proxy-advisory-firms-back-allergan-in-battle-with-dissident-shareholder-appaloosa/2476472/Allergan said Monday that proxy advisory firms Institutional Shareholder Services (ISS) and Glass Lewis have recommended that shareholders vote for all of the board’s proposals at its annual meeting on May 1, and against hedge fund Appaloosa’s proposal calling for the immediate separa
- Novartis Announces FDA BLA Acceptance of Brolucizumab for Wet AMDhttps://modernod.com/news/novartis-announces-fda-filing-acceptance-and-priority-review-of-brolucizumab-for-wet-amd/2476468/Novartis announced that the FDA has accepted the company’s biologics license application (BLA) for brolucizumab (RTH258) for the treatment of wet age-related macular degeneration (AMD). Novartis used a priority review voucher to expedite FDA review and anticipates launching brolucizumab, if
- Alimera Sciences Appoints Samer Kaba, MD, as Chief Medical Officerhttps://modernod.com/news/alimera-sciences-appoints-samer-kaba-md-as-chief-medical-officer/2476464/Alimera Sciences announced an expansion of its leadership team with the appointment of Samer Kaba, MD, as Chief Medical Officer, effective April 4, 2019. “I am very pleased that Samer will be joining us in this new position as he will bring both a physician’s perspect
- US Ophthalmologists Push to Remove Roadblocks to Patients’ Access to Medical and Surgical Eye Carehttps://modernod.com/news/us-ophthalmologists-push-to-remove-roadblocks-to-patients-access-to-medical-and-surgical-eye-care/2476461/More than 400 eye physicians and surgeons from across the United States are in Washington, DC, to urge Congress to end federal policies that delay patients’ access to quality medical and surgical eye care. As part of its annual visit to Capitol Hill, the American Academy of Ophthalmology (AAO) is
- Texas Tech Medical School to End Use of Race in Admissionshttps://modernod.com/news/texas-tech-medical-school-to-end-use-of-race-in-admissions/2476462/Texas Tech University’s medical school has agreed to end its consideration of race in selecting candidates for admission, an outcome actively sought by the Trump administration. The Texas Tech University Health Sciences Center submitted to pressure from the Education Department’s Offi
- I-MED Pharma Becomes Authorized Canadian Distributor for OrCam MyEye 2https://modernod.com/news/i-med-pharma-becomes-authorized-canadian-distributor-for-orcam-myeye-2/2476463/I-MED Pharma, a Canadian company specializing in dry eye diagnosis and management, announced the signing of an authorized Canadian distribution agreement with OrCam for its MyEye 2 assistive technology device for the blind and visually impaired. The OrCam MyEye 2 is a tiny, portable, artif